{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:03:48Z","timestamp":1776121428846,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.urolonc.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,8,21]],"date-time":"2016-08-21T05:30:58Z","timestamp":1471757458000},"page":"418.e17-418.e26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune signature of urothelial cancer associated with grade, recurrence, and invasion"],"prefix":"10.1016","volume":"34","author":[{"given":"Usha","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitu","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawan","family":"Vasudeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayan K.","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.04.013_bib1","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2016.04.013_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10555-009-9196-5","article-title":"Strategies for molecular expression profiling in bladder cancer","volume":"28","author":"Mitra","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.urolonc.2016.04.013_bib3","first-page":"611","article-title":"Novel insights into the mechanism of action of intravesical immunomodulators","volume":"19","author":"Mitropoulos","year":"2005","journal-title":"In Vivo"},{"key":"10.1016\/j.urolonc.2016.04.013_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5489\/cuaj.777","article-title":"Update on the management of non-muscle invasive bladder cancer","volume":"4","author":"Aldousari","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2016.04.013_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0302-2838(03)00047-2","article-title":"Low IL-1\u03b1 expression in bladder cancer tissue and survival","volume":"43","author":"Seddighzadeh","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.eururo.2008.05.027","article-title":"Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker","volume":"56","author":"Pignot","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.urolonc.2016.04.013_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1373\/49.1.23","article-title":"Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer","volume":"49","author":"S\u00e1nchez-Carbayo","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.urolonc.2016.04.013_bib9","series-title":"World Health Organization classification of tumours: Pathology and genetics of tumours of the urinary system and male genital organ","first-page":"110","article-title":"Non-invasive urothelial tumours","author":"Sauter","year":"2004"},{"key":"10.1016\/j.urolonc.2016.04.013_bib10","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"issue":"6 Suppl 4","key":"10.1016\/j.urolonc.2016.04.013_bib11","first-page":"S199","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2016.04.013_bib12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/sj.bjc.6603104","article-title":"The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival","volume":"94","author":"Evans","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2016.04.013_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/clim.2001.5163","article-title":"Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery","volume":"102","author":"Galizia","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib14","doi-asserted-by":"crossref","unstructured":"Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother, 2006;55:734\u2013743.","DOI":"10.1007\/s00262-005-0045-2"},{"key":"10.1016\/j.urolonc.2016.04.013_bib15","first-page":"60","article-title":"Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma","volume":"17","author":"Lech-Maranda","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.urolonc.2016.04.013_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1081\/IMM-120019205","article-title":"Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma","volume":"32","author":"Agarwal","year":"2003","journal-title":"Immunol Invest"},{"key":"10.1016\/j.urolonc.2016.04.013_bib17","doi-asserted-by":"crossref","first-page":"26041","DOI":"10.1074\/jbc.M602222200","article-title":"NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages","volume":"281","author":"Cao","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2016.04.013_bib18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4049\/jimmunol.1500146","article-title":"IL-10 Production in macrophages is regulated by a TLR-driven CREB-mediated mechanism that is linked to genes involved in cell metabolism","volume":"195","author":"Sanin","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib19","doi-asserted-by":"crossref","first-page":"31868","DOI":"10.1074\/jbc.274.45.31868","article-title":"Interleukin-10 signaling blocks inhibitor of \u03baB kinase activity and nuclear factor \u03baB DNA binding","volume":"274","author":"Schottelius","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2016.04.013_bib20","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: the master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1189\/jlb.0705358","article-title":"Interleukin-10 and the immune response against cancer: a counterpoint","volume":"78","author":"Mocellin","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3844\/ajisp.2012.1.9","article-title":"Role of IL-10 in urinary bladder carcinoma and Bacillus Calmette-Guerin immunotherapy","volume":"8","author":"Luo","year":"2012","journal-title":"Am J Immunol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/pr.55.2.4","article-title":"Interleukin-10 therapy\u2014review of a new approach","volume":"55","author":"Asadullah","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.urolonc.2016.04.013_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4161\/onci.20640","article-title":"Blocking IL-10 enhances bacillus Calmette-Gu\u00e9rin induced T helper Type 1 immune responses and anti-bladder cancer immunity","volume":"1","author":"Luo","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.urolonc.2016.04.013_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1440-1711.1999.00795.x","article-title":"The role of CTLA-4 in the regulation of T cell immune responses","volume":"77","author":"McCoy","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.21155","article-title":"CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction","volume":"117","author":"Contardi","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2016.04.013_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib28","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.04.013_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production","volume":"11","author":"Stefania Laurent","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2016.04.013_bib30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2016.04.013_bib31","doi-asserted-by":"crossref","first-page":"aaa6566","DOI":"10.1126\/science.aaa6566","article-title":"Innate lymphoid cells: a new paradigm in immunology","volume":"348","author":"Eberl","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2016.04.013_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CJI.0b013e3181c01fcb","article-title":"Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy","volume":"33","author":"Mangsbo","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.urolonc.2016.04.013_bib33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2008.162842","article-title":"Anti-CTLA-4 treatment induces IL-10-producing ICOS+regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis","volume":"58","author":"Coquerelle","year":"2009","journal-title":"Gut"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916300473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916300473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:08:15Z","timestamp":1761041295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916300473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1078143916300473"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.04.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune signature of urothelial cancer associated with grade, recurrence, and invasion","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}